Tag: Tiara-II

Neovasc Receives Approval to Proceed with Phase 2 of TIARA-II Study from Clinical Regulators in Germany and the UK

VANCOUVER, Jan 29, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it has completed the Phase 1 requirements of the […]